Search | Clinical Trials Finder

Conditions: Dementia, Alzheimer Type
Interventions: Physical activity, Successful Aging; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 60 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Alzheimer Disease, Dementia of Alzheimer Type
Interventions: ATH-1017, Placebo; Drug
Lead sponsor: LeonaBio; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 7
States / cities: Santa Ana, California • West Palm Beach, Florida • Decatur, Georgia + 4 more

Conditions: Early Alzheimer's Disease
Interventions: E2609; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota

Conditions: Alzheimer's Disease, Dementia
Interventions: Drug: NIC5-15, Placebo; Drug
Lead sponsor: Humanetics Corporation; Industry
Eligibility: 40 Years to 95 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Alzheimer's Disease
Interventions: ST101, Placebo; Drug
Lead sponsor: Sonexa Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 15
States / cities: Costa Mesa, California • Redlands, California • San Diego, California + 12 more

Conditions: Dementia Moderate, Dementia, Mild, Alzheimer Disease
Interventions: Xanamem, Placebo; Drug
Lead sponsor: Actinogen Medical; Industry
Eligibility: 50 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 20
States / cities: Carlsbad, California • Orange, California • Sherman Oaks, California + 17 more

Conditions: Depression, Stress, Psychological, Self Efficacy, Loneliness, Social Isolation, Health Care Utilization, Dementia, Dementia Alzheimers, Dementia of Alzheimer Type, Dementia, Vascular, Dementia Frontal, Dementia, Lewy Body, Dementia, Mixed, Dementia in Parkinsons Disease, Dementia, HIV, Dementia Frontotemporal, Dementia, Multi-Infarct
Interventions: Building Better Caregivers Workshop, Attention Control; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alzheimer Disease, Dementia
Interventions: MPC-7869; Drug
Lead sponsor: Myrexis Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 23
States / cities: Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 20 more

Conditions: Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
Interventions: AXS-05 (dextromethorphan-bupropion), Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 65 Years to 90 Years
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 45
States / cities: Peoria, Arizona • Tempe, Arizona • Long Beach, California + 35 more

Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions: E2814, Lecanemab, Matching Placebo (E2814); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more

Conditions: Dementia, Mild, Depression
Interventions: Decision aid; Other
Lead sponsor: University of Washington; Other
Eligibility: 65 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Alzheimer's Disease
Interventions: Brexpiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 55 Years to 91 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Dementia, Alzheimer Type
Interventions: ABC Clinical Program, BCN; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: Placebo, AVP-786; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 93
States / cities: Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 68 more

Conditions: Alzheimer's Disease
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2026
U.S. locations: 8
States / cities: Jacksonville, Florida • Indianapolis, Indiana • Boston, Massachusetts + 5 more

Conditions: Caregiver Stress, Dementia, Alzheimer Disease, Lewy Body Dementia, Parkinson Disease Dementia, Frontotemporal Dementia
Interventions: Algorithm, Random Match; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dementia, Alzheimer Type
Interventions: Xanamem™, Placebo (for Xanamem™); Drug
Lead sponsor: Actinogen Medical; Industry
Eligibility: 50 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 14
States / cities: Tucson, Arizona • Los Angeles, California • Poway, California + 11 more

Conditions: Dementia of Alzheimer Type
Interventions: Physical activity program, Successful Aging; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 60 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: grape seed polyphenolic extract, resveratrol; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alzheimer Disease, Mild Cognitive Impairment
Interventions: Active Transcranial Direct Current Stimulation (tDCS), Sham Transcranial Direct Current Stimulation (tDCS); Device
Lead sponsor: Minneapolis Veterans Affairs Medical Center; Federal
Eligibility: 60 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions: Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, Matching Placebo (E2814); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 490 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more

Conditions: Mild Cognitive Impairment
Interventions: Lithium Carbonate, Placebo oral capsule; Drug
Lead sponsor: Ariel Gildengers, MD; Other
Eligibility: 60 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Alzheimer's Disease
Interventions: Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2), Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 93
States / cities: Tempe, Arizona • Tucson, Arizona • Conway, Arkansas + 84 more

Conditions: Alzheimer's Disease
Interventions: Donepezil, AZD3480; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Phoenix, Arizona • Brooksville, Florida • Hallandale, Florida

Search by objective public record fields.

Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)"

A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease

A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects

A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease

Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

Rural Dementia Caregiver Project

Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

Decision Making Tool for Firearm Storage

A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Technology Intervention to Support Caregiving for Alzheimer's Disease (I-CARE)

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Dominantly Inherited Alzheimer Network (DIAN)

A Study of Caregiver Connections Via Technology in Dementia

A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

Reducing African American's Alzheimer's Risk Through Exercise-Mild Cognitive Impairment (RAATE-MCI)

BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)

tDCS and Cognitive Training for Mild Cognitive Impairment and Alzheimer's Dementia

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

Lithium As a Treatment to Prevent Impairment of Cognition in Elders

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)